Status:
COMPLETED
Comparing the Efficacy of Hybrid, High-dose Dual and Bismuth Quadruple Therapies
Lead Sponsor:
Kaohsiung Veterans General Hospital.
Conditions:
Helicobacter Pylori Infection
Eligibility:
All Genders
20-90 years
Phase:
PHASE3
Brief Summary
Both hybrid and high-dose dual therapies developed by the scholars from Taiwan can achieve a high eradication rate for clarithromycin-resistant strains, and have a great potential to replace bismuth q...
Detailed Description
Bismuth quadruple therapy has been recommended as a choice of the first-line treatment for H. pylori infection in several important international consensuses. However, it is associated with a high fre...
Eligibility Criteria
Inclusion
- Consecutive H pylori-infected outpatients, at least 20 years of age, with endoscopically proven peptic ulcer diseases or gastritis
Exclusion
- previous H pylori-eradication therapy
- ingestion of antibiotics or bismuth within the prior 4 weeks
- patients with allergic history to the medications used
- patients with previous gastric surgery
- the coexistence of serious concomitant illness (for example, decompensated liver cirrhosis, uremia)
- pregnant women
Key Trial Info
Start Date :
September 3 2018
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
December 31 2021
Estimated Enrollment :
918 Patients enrolled
Trial Details
Trial ID
NCT03779074
Start Date
September 3 2018
End Date
December 31 2021
Last Update
October 26 2023
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Kaohsiung Veterans General Hospital
Kaohsiung City, Taiwan, 813